Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation

NCT04447469 is registered in ClinicalTrials.gov with Kiniksa Pharmaceuticals International, plc as lead sponsor.

NCT NCT04447469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04447469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Phase
Phase 2/3
Overall status
Completed
Start date
July 28, 2020
Completion date
January 14, 2022
Enrollment
814 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

covid